公开(公告)号：US20190287656A1

公开(公告)日：2019-09-19

申请号：US16422568

申请日：2019-05-24

申请人： Nantomics, LLC

发明人： Andrew Nguyen ,  John Zachary Sanborn ,  Stephen Charles Benz

IPC分类号： G16C20/60 ,  G16B35/00 ,  G16H20/40 ,  G16H10/40 ,  G16B20/30 ,  C12Q1/70 ,  A61K39/00

摘要： Contemplated antiviral/cancer treatments comprise analysis of neoepitopes from viral DNA that has integrated into the host genome, and design of immunotherapeutic agents against such neoepitopes.

公开(公告)号：US20190226034A1

公开(公告)日：2019-07-25

申请号：US16369618

申请日：2019-03-29

申请人： NantOmics, LLC

发明人： Shahrooz Rabizadeh ,  Patrick Soon-Shiong ,  Stephen Charles Benz

IPC分类号： C12Q1/6886 ,  G16B30/00

摘要： Specific mutations of FGFR3 (S249C) and of TP53 (V272M) are identified as being characteristic of breast cancer, and of having utility in diagnosis and prognosis of an individual with breast cancer. Systems and methods useful for identification of such mutations are also presented.

公开(公告)号：US20190178866A1

公开(公告)日：2019-06-13

申请号：US16126772

申请日：2018-09-10

申请人： NantOmics, LLC

发明人： David B. KRIZMAN ,  Todd HEMBROUGH ,  Eunkyung AN

IPC分类号： G01N33/483 ,  G01N33/68 ,  G01N33/574

摘要： Methods are provided for quantifying the cyclin-dependent kinase inhibitor 2A protein (p16) p16 protein directly in biological samples that have been fixed in formalin by SRM/MRM mass spectrometry. A protein sample is prepared from the biological sample using, for example, the Liquid Tissue reagents and protocol and the p16 protein is quantitated in the resulting sample by quantitating in the protein sample at least one fragment peptide from p16. Peptides can be quantitated in modified or unmodified form. An example of a modified form of a p16 peptide is phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence.

公开(公告)号：US20190099475A1

公开(公告)日：2019-04-04

申请号：US15565203

申请日：2016-04-08

申请人： NANTOMICS, LLC

发明人： Stephen Charles Benz ,  Andrew Nguyen ,  Charles Joseph Vaske ,  John Zachary Sanborn

IPC分类号： A61K39/00 ,  C12N5/0783

摘要： Certain universal neoepitopes and cancer specific neoepitopes and methods therefor are presented that may be used in immunotherapy and cancer diagnosis. Preferred therapeutic and diagnostic compositions include antibodies or fragments thereof that bind to neoepitopes on cancer cells.

公开(公告)号：US20240321392A1

公开(公告)日：2024-09-26

申请号：US18740319

申请日：2024-06-11

申请人： Nantomics LLC

发明人： Andrew Nguyen ,  John Zachary Sanborn ,  Stephen Charles Benz

IPC分类号： G16B20/30 ,  A61K39/00 ,  C12Q1/70 ,  G16B35/00 ,  G16C20/60 ,  G16H10/40 ,  G16H20/10 ,  G16H20/40 ,  G16H70/60

CPC分类号： G16B20/30 ,  A61K39/0011 ,  C12Q1/708 ,  G16B35/00 ,  G16C20/60 ,  G16H10/40 ,  G16H20/10 ,  G16H20/40 ,  G16H70/60 ,  A61K39/00 ,  C12Q2600/106 ,  C12Q2600/156

摘要： Contemplated antiviral/cancer treatments comprise analysis of neoepitopes from viral DNA that has integrated into the host genome, and design of immunotherapeutic agents against such neoepitopes.

公开(公告)号：US20240229022A1

公开(公告)日：2024-07-11

申请号：US18614465

申请日：2024-03-22

申请人： Nantomics LLC

发明人： Patrick Soon-Shiong ,  Shahrooz Rabizadeh ,  Kathleen Danenberg

IPC分类号： C12N15/11 ,  C12N15/10 ,  C12Q1/6876

CPC分类号： C12N15/11 ,  C12N15/1003 ,  C12Q1/6876 ,  C12N2320/51 ,  C12Q2565/00

摘要： RNA from a biological fluid is stabilized during isolation and/or storage using DNA. In especially preferred aspects, the RNA is cfRNA and/or ctRNA, and the biological fluid is blood.

公开(公告)号：US11954856B2

公开(公告)日：2024-04-09

申请号：US17881578

申请日：2022-08-04

申请人： NantOmics, LLC

发明人： Bing Song ,  Liudmila A Beziaeva ,  Shahrooz Rabizadeh

IPC分类号： G06T7/00 ,  G06T7/11 ,  G06T7/136

CPC分类号： G06T7/0012 ,  G06T7/11 ,  G06T7/136 ,  G06T2207/10056 ,  G06T2207/20041 ,  G06T2207/20104 ,  G06T2207/20152 ,  G06T2207/30024 ,  G06T2207/30096 ,  G06T2207/30242

摘要： Techniques are provided for determining a cell count within a whole slide pathology image. The image is segmented using a global threshold value to define a tissue area. A plurality of patches comprising the tissue area are selected. Stain intensity vectors are determined within the plurality of patches to generate a stain intensity image. The stain intensity image is iteratively segmented to generate a cell mask using a local threshold value that is and gradually reduced after each iteration. A chamfer distance transform is applied to the cell mask to generate a distance map. Cell seeds are determined on the distance map. Cell segments are determined using a watershed transformation, and a whole cell count is calculated for the plurality of patches based on the cell segments. A client device may be configured for real-time cell counting based on the whole cell count.

公开(公告)号：US20240079089A1

公开(公告)日：2024-03-07

申请号：US18506554

申请日：2023-11-10

申请人： Nantomics LLC

发明人： Andrew Nguyen ,  John Zachary Sanborn ,  Shahrooz Rabizadeh

IPC分类号： G16B25/10 ,  C12Q1/6827 ,  C12Q1/6869 ,  G16B20/00 ,  G16B20/20 ,  G16B30/10 ,  G16B40/00 ,  G16H50/20 ,  G16H50/30

CPC分类号： G16B25/10 ,  C12Q1/6827 ,  C12Q1/6869 ,  G16B20/00 ,  G16B20/20 ,  G16B30/10 ,  G16B40/00 ,  G16H50/20 ,  G16H50/30 ,  G01N2570/00 ,  Y02A90/10

摘要： Systems and methods for prediction of the treatment outcome for immune therapy are presented in which omics data of a patient tumor sample are used. Most typically, the omics data are processed to identify mutational signatures (especially APOBEC/POLE signatures), immune checkpoint expression, and MSI status as leading indicators to predict the treatment outcome for immune therapy. Such prediction advantageously integrates various parameters that would otherwise, when individually considered, skew prediction outcome.

公开(公告)号：US11756651B2

公开(公告)日：2023-09-12

申请号：US16767366

申请日：2018-12-21

申请人： NANTOMICS, LLC ,  NANTBIO, INC. ,  NANT HOLDINGS IP, LLC

发明人： Kevin B. Givechian ,  Kamil A. Wnuk ,  Chad Garner ,  Stephen Charles Benz ,  Hermes J. Garban ,  Shahrooz Rabizadeh ,  Kayvan Niazi ,  Patrick Soon-Shiong

IPC分类号： G16B25/10 ,  C12Q1/6886

CPC分类号： G16B25/10 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158

摘要： An immune gene expression signature is associated with favorable clinical features in Treg-enriched tumor samples and can be used to predict immunogenicity of a tumor, overall survival, and/or chemosensitivity.

公开(公告)号：US20230274796A1

公开(公告)日：2023-08-31

申请号：US18096527

申请日：2023-01-12

申请人： NantOmics, LLC

发明人： Jeremi Sudol ,  Kamil Wnuk

IPC分类号： G16B40/00 ,  G16B5/20 ,  G06N3/08 ,  G06N3/044 ,  G06N3/045

CPC分类号： G16B40/00 ,  G16B5/20 ,  G06N3/08 ,  G06N3/044 ,  G06N3/045

摘要： Techniques are provided for predicting MHC-peptide binding affinity. A plurality of training peptide sequences is obtained, and a neural network model is trained to predict MHC-peptide binding affinity using the training peptide sequences. An encoder of the neural network model comprising an RNN is configured to process an input training peptide sequence to generate a fixed-dimension encoding output by applying a final hidden state of the RNN at intermediate state outputs of the RNN to generate attention weighted outputs, and linearly combining the attention weighted outputs. A fully connected layer following the encoder is configured to process the fixed-dimension encoding output to generate an MHC-peptide binding affinity prediction output. A computing device is configured to use the trained neural network to predict MHC-peptide binding affinity for a test peptide sequence.